Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program

By Cory Renauer - Feb 10, 2021 at 1:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.

A large part of a $5 billion bet that Gilead Sciences (GILD 0.43%) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (GLPG -0.48%), when the partners announced all clinical trials with the experimental autotaxin inhibitor would be discontinued on Wednesday morning.

In a mid-stage idiopathic pulmonary fibrosis (IPF) study, patients treated with ziritaxestat showed lung function improvements, while those given a placebo declined significantly. The candidate also produced compelling efficacy data in a mid-stage study with systemic sclerosis patients.

Frustrated investor with head in hand and an open laptop.

Image source: Getty Images.

Mid-stage efficacy data were so good that it was most likely a safety concern that raised the drug's risk-to-benefit ratio up to an untenable level. The partners haven't set a date, but we'll find out more when they present detailed results at a future medical conference. 

This isn't the first time Gilead's partnership with Galapagos disappointed investors. Last October, Galapagos also reported a mid-stage clinical-trial failure with an experimental osteoarthritis treatment called GLPG1972. Gilead hadn't executed its option to in-license GLPG1972, but a Galapagos-partnered program Gilead Sciences had licensed imploded around the same time.

Last fall, Gilead gave up on developing filgotinib, a potential rheumatoid arthritis treatment that had been expected to generate blockbuster sales before the FDA refused to approve it last summer.

Excluding sales of its COVID-19 treatment, Veklury (remdesivir), Gilead Sciences reported total revenue that contracted 3% last year. Without any potential blockbusters in late-stage development, the company is depending on sales of Trodelvy (a new breast cancer drug the company acquired for around $21 billion last September) to drive growth. After earning FDA approval last April, Trodelvy sales reached just $137 million in 2020. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.48 (0.43%) $0.27
Galapagos Stock Quote
Galapagos
GLPG
$55.62 (-0.48%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.